APOE and metabolic syndrome: Second, related pathways have clinical translatability: CETP inhibitors (targeting cholesterol ester transport) are approved for dyslipidemia and reduce VSMC dysfunction in preclinical AD models,[26] while APOE-modulating therapies are tested in cardiovascular diseases.We do not claim immediate clinical application, but propose a stepwise path: first validate targets in human AD tissues, then test their predictive value in large cohorts, and finally repurpose safe, existing agents in early-phase trials – laying the groundwork for future clinical translation.